Cormorant Asset Management, LP Forma Therapeutics Holdings, Inc. Transaction History

Cormorant Asset Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$5.1 - $10.0 $4.57 Million - $8.96 Million	-896,147 Reduced 22.03%	3,172,204 $21.9 Million
Q1 2022 May 16, 2022	SELL	$8.34 - $14.69 $4.77 Million - $8.4 Million	-571,644 Reduced 12.32%	4,068,351 $37.8 Million
Q4 2021 Feb 14, 2022	SELL	$13.6 - $24.89 $1.09 Million - $2 Million	-80,500 Reduced 1.71%	4,639,995 $66 Million
Q3 2021 Nov 15, 2021	SELL	$21.22 - $25.7 $23,214 - $28,115	-1,094 Reduced 0.02%	4,720,495 $109 Million
Q2 2021 Aug 16, 2021	BUY	$22.86 - $30.95 $36,324 - $49,179	1,589 Added 0.03%	4,721,589 $118 Million
Q1 2021 May 17, 2021	BUY	$24.58 - $42.82 $6.39 Million - $11.1 Million	260,000 Added 5.83%	4,720,000 $132 Million
Q4 2020 Feb 16, 2021	BUY	$34.9 - $51.08 $37.7 Million - $55.2 Million	1,080,627 Added 31.98%	4,460,000 $156 Million
Q2 2020 Aug 14, 2020	BUY	$39.0 - $46.49 $132 Million - $157 Million	3,379,373 New	3,379,373 $153 Million

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.